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Abstract 
Background: Women experiencing incarceration (WEI) engage in high rates of sex‑ and drug‑related behavior that 
places them at risk for HIV. Pre‑exposure prophylaxis (PrEP) is an efficacious means of reducing HIV acquisition. There 
is a general lack of knowledge regarding PrEP among women at elevated risk, and only a small percentage of at‑risk 
women are currently engaged in PrEP care. The period of incarceration represents an opportunity to identify at‑risk 
women, initiate PrEP during incarceration, and establish linkage to community‑based PrEP care upon release from 
incarceration. Further, post‑release is a time period that is particularly risky, and there are numerous barriers, including 
substance use, that may impede linkage to community‑based care in the absence of intervention. The current pro‑
tocol describes plans for the development and pilot randomized controlled trial (RCT) of an intervention to promote 
PrEP uptake during incarceration and facilitate linkage to community‑based PrEP care post‑release.
Methods/design: The motivational interviewing‑navigation (MI‑NAV) study intervention is being developed, refined, 
and tested over three phases within the framework of the social ecological model. All phases of the study are being 
conducted at a women’s correctional facility and community‑based PrEP provider located in the Northeastern region 
of the United States. Phase 1 consists of individual qualitative interviews to be conducted with key stakeholders 
(n = 6–10) from the community‑based PrEP care site and (n = 6–10) from the women’s correctional facility, as well as 
with (n = 18–30) WEI. Recruitment for Phase 1 was initiated in November 2017. In Phase 2, MI‑NAV will be piloted with 
a small cohort (n = 8–12) of WEI and will be refined based upon participant feedback. During Phase 3, a pilot RCT of 
MI‑NAV and a standard of care condition will be conducted with 80 WEI. RCT participants will complete baseline and 
follow‑up assessments 1, 3, and 6 months post‑release. The primary study outcome is linkage to community‑based 
PrEP care, verified via medical records.
Discussion: This study will develop and evaluate a psychosocial intervention (MI‑NAV) to promote PrEP uptake and 
facilitate linkage to community‑based PrEP care among women at‑risk for HIV. It is expected that, as a result of this 
project, the feasibility, acceptability, and preliminary efficacy of MI‑NAV will be determined. If found to be efficacious, 
this intervention has the potential to reduce HIV acquisition in a high‑need, underserved community.
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Background
The criminal-justice involved population in the United 
States (US) is among the most vulnerable and heav-
ily impacted by HIV; women experiencing incarcera-
tion (WEI) have been found to be as much as 15 times 
more likely to be HIV infected than women in the general 
population [1]. They have also consistently been found 
to report high levels of HIV risk behavior. A large study 
of female jail detainees found a 24.3% rate of weekly sex 
exchange in the past year and an 18.8% rate of history of 
injection drug use [2]. Similarly high rates of HIV-related 
sex and drug risk behavior have been found in other stud-
ies of WEI (e.g., [3]).
The period immediately following release from incar-
ceration may be a particularly high risk period for HIV-
related risk behavior. Binswanger et  al. [4] observed 
consistently high rates of unprotected sex 2  weeks and 
3 months post-release among a sample of women. Com-
pared to men, women recently released from prison 
reported engaging in a significantly greater average num-
ber of HIV sex risk behaviors (2.31 vs. 4.73) and HIV 
drug risk behaviors (.07 vs 2.72), within the past month 
[5]. Qualitative interviews with recently incarcerated 
individuals revealed that both sex and drug risk behav-
iors were prevalent during the post-release period, the 
highest rates of HIV-risk behaviors occurred during the 
first few days post-release, there was a general lack of 
knowledge of HIV, and there were significant barriers 
to accessing health care and medications post-release 
[6]. Therefore, there is a strong need for effective inter-
ventions that reduce HIV risk among this population, 
especially during the high risk period immediately after 
release from incarceration.
One potential approach to addressing the HIV epi-
demic among at-risk women is through the use of pre-
exposure prophylaxis (PrEP) [7, 8]. PrEP is a prevention 
intervention that currently entails the daily use of a sin-
gle-tablet combination antiretroviral medication (emtric-
itabine/tenofovir) by HIV-uninfected individuals and is 
effective at preventing HIV seroconversion when taken 
every day [9–11]. For example, Partners PrEP demon-
strated between 86 and 90% risk reduction for acquir-
ing HIV in individuals with detectable levels of the study 
drug (i.e., PrEP) in their blood [11]. In addition, a 70% 
risk reduction in HIV infection was observed in adherent 
participants of the Bangkok Tenofovir Study [9].
While PrEP may be an effective strategy for preventing 
HIV acquisition in at-risk women, there has been little 
uptake of PrEP among women in the US. Indeed, PrEP 
prescriptions for women accounted for only 3% of all 
PrEP prescriptions in a national sample of persons with 
commercial health insurance in the US through 2014 
[12]. Medicaid data from the state of New York tell a 
similar story, with sharp increases over the last 5 years in 
the number of PrEP prescriptions for men and only mod-
est increases for women [13]. A chief contributor to the 
underutilization of PrEP among US women appears to be 
a general lack of knowledge regarding PrEP and a limited 
ability to accurately assess their level of risk, even among 
women who are at elevated risk for HIV [14–17]. How-
ever, there is significant interest in PrEP among at-risk 
women following psychoeducation regarding PrEP care, 
if barriers such as cost and accessibility can be addressed 
[15, 16]. In fact, in a recent study conducted by Rutledge 
and colleagues [8], 90% of WEI who were eligible for 
PrEP claimed they would try PrEP if their provider rec-
ommended a prescription.
One potential approach to improve PrEP uptake among 
at-risk women is Motivational Interviewing (MI) [18, 
19]. MI is a collaborative, nonconfrontational approach 
to discussing and facilitating behavior change. HIV risk 
reduction interventions combining MI and skills train-
ing have been found to reduce HIV risk behavior among 
at-risk women [20, 21]. Further, MI has been found to 
significantly reduce unprotected intercourse and needle 
sharing among recently incarcerated women at risk for 
HIV [22]. A relatively recent systematic review of stud-
ies examining HIV risk reduction interventions among 
adults with criminal justice involvement found that MI 
shows promise in this population [23].
Formerly incarcerated women face individual-, inter-
personal-, community-, and structural-level barriers to 
accessing community-based care post-release. Substance 
use and depression, which are highly prevalent within 
this population, are linked to poor treatment engagement 
and adherence [24–27]. Stigma, lack of transportation, 
and cost of care also hamper their ability to access treat-
ment services in the community [28, 29]. Facilitators of 
care include being linked to community-based care, hav-
ing appointments scheduled upon release, and receiving 
health education during incarceration [29]. Consistent 
with these findings, persons living with HIV who are 
linked to care at the time of release from incarceration 
are more likely to have a regular source of care compared 
to those who do not receive this service [30].
A potential strategy to more effectively link women 
recently released from incarceration to PrEP care ser-
vices is through the use of patient navigators (NAVs). 
Traditionally, NAVs are individuals who help patients 
navigate the complex landscape of the healthcare sys-
tem. This often takes the form of communicating a 
patient’s concerns with their healthcare provider, assist-
ing patients with scheduling appointments, arranging 
transportation to appointments, and connecting patients 
with other necessary resources (e.g., housing, clothing, 
translation services). NAVs have been used since 1990 
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as a means of increasing health screenings and linkage 
to services. This model has been tested most commonly 
in oncology and is a proven evidence-based practice for 
linking and engaging at-risk populations to treatment 
[31]. Bradford et  al. [32] reported the NAV model as 
having “promise for improving access to HIV care” and 
reducing health disparities among HIV-infected disad-
vantaged populations. However, little scientific advance-
ment has occurred over the past decade in examining the 
effectiveness of culturally-tailored NAV interventions 
among HIV-infected populations. Further, no research, 
to date, has examined the utility of NAVs for linkage to 
PrEP among at-risk populations.
However, NAV interventions have been used to link 
women released from incarceration to other types of 
community-based care. For example, Scott and Dennis 
[33] evaluated the efficacy of monthly sessions with a 
“Linkage Manager” for women with substance problems 
during the 90-day period post-release from incarceration. 
Linkage Managers used MI with participants to provide 
feedback about their behavior, discuss barriers to mak-
ing a change, and discuss motivation to change behavior. 
They also scheduled treatment appointments for partici-
pants and accompanied them to intake appointments. 
Participants who were assigned to receive the Linkage 
Manager sessions were more likely to participate in sub-
stance use disorder (SUD) treatment, return to treatment 
sooner, and be abstinent from alcohol and drugs, relative 
to participants in a “reentry as usual” control condition.
The conceptual framework that undergirds the pre-
sent study is the social ecological model (SEM) [34]. The 
SEM has a focus extending beyond the individual, tak-
ing a crucial stance that shifts responsibility for reduc-
ing health inequalities away from individuals onto social 
and structural factors and the systems in which individu-
als are situated. Recently, the “Ecological Model of Fac-
tors that Impact Pre-Exposure Prophylaxis Attitudes and 
Uptake among Black MSM” was developed in response 
to a lack of multi-level PrEP research [35]. This model 
makes explicit the need to understand how structural, 
social, and individual factors all combine to affect PrEP 
uptake. Building on this model in the current study, the 
SEM will be used as the lens to understand how incarcer-
ation affects an at-risk woman’s behavior, relationships, 
risk environment, and subsequent ability to initiate and 
adhere to PrEP care post-release.
Present study
This project will address the great need to engage women 
at risk for HIV in PrEP care, capitalizing on a period of 
incarceration as an opportunity to reach a high-need, 
underserved population. While incarceration is a difficult 
time in women’s lives, it can also be a time of opportunity 
to obtain healthcare that they might not otherwise obtain 
and to focus on rebuilding a post-incarceration life with 
some ability to concentrate on themselves in the absence 
of other competing demands. We will combine an MI 
intervention to promote PrEP initiation during incarcera-
tion, followed by a NAV intervention to facilitate linkage 
to community-based PrEP care upon release from incar-
ceration among at-risk, cisgender women, referred to 
as the motivational interviewing-navigation (MI-NAV) 
intervention. This study has 3 specific aims and will be 
conducted over 3 phases. The first aim is to develop the 
intervention materials, the second is to test the inter-
vention and make modifications as necessary, and the 
third is to complete a pilot RCT comparing MI-NAV to 
a control condition. The aims of the study coincide with 
the study phases. The study was designed in this manner 
so that there are multiple points of feedback and refine-
ment, prior to launch of the pilot RCT (see Fig.  1) [36, 
37]. Phase 1 will consist of individual interviews with 
WEI at risk for HIV and with key stakeholders (e.g. 
administrators, health care providers, social/case work-
ers) at a correctional facility and a community-based 
PrEP care site. The information gathered from these 
interviews will inform the development of intervention 
materials and an implementation manual. In Phase 2, 
the intervention materials and implementation approach 
will be tested with WEI who are at risk for HIV. Feedback 
from pilot participants, study staff, and stakeholders will 
guide refinement of the intervention and implementation 
approach. In Phase 3, we will conduct a pilot RCT of at-
risk WEI comparing MI-NAV to a control condition that 
approximates standard-of-care (SOC). Data will be col-
lected on successful linkage to PrEP care, which is opera-
tionalized as receiving a prescription for PrEP within 
3 months post-release from incarceration. Data will also 
be collected on the acceptability and feasibility of the 
intervention and implementation approach.
Methods/design
Participants and setting
A women’s correctional facility and a community-based 
PrEP care site, both located in the Northeastern US, 
will serve as the recruitment and implementation sites 
for this study. The correctional facility is an integrated, 
statewide jail and prison that houses all females await-
ing trial and/or serving a sentence. On average, there are 
179 new female incarcerations per month at this facility. 
In 2015, 2150 women were incarcerated, and over 80% 
were sentenced to < 6  months. All inmates (sentenced 
and awaiting trial) are screened and referred, as deemed 
appropriate, to SUD treatment, which uses a four-tier 
model of treatment intensity (from most to least inten-
sive: modified residential therapeutic community, day 
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treatment, counseling groups, and peer support). In addi-
tion, the facility offers in-house medications for opioid 
use disorder (OUD) as necessary. The medication pro-
vided is determined clinically, based primarily on past 
experiences, patient preference, and logistical considera-
tions. This correctional facility is working to establish a 
Gilead Medication Assistance program to offer PrEP to 
inmates. The community-based PrEP care site is a non-
profit health center that offers a wide range of health care 
services including screening and testing for STIs, HIV 
testing and counseling, family planning services, repro-
ductive healthcare for women and men, and PrEP care. 
This health center is currently staffed by 4 physicians, 2 
full-time and 7 part-time nurse practitioners and physi-
cians’ assistants, and 3 nurses.
Six to ten key stakeholders will be recruited from each 
of the sites to participate in the individual interviews. 
Study staff will attend staff meetings at the sites to intro-
duce the study to stakeholders and invite their participa-
tion in the individual interviews. Participation will not 
be required by their respective employers, and there will 
be no occupational consequences for completing or not 
completing an individual interview. No data collected 
from stakeholders will be shared with their employers. 
Once a potentially eligible staff member has been identi-
fied, a research assistant will contact them, describe the 
nature of the interview, and coordinate a time to conduct 
the individual interview if the individual is eligible and 
interested in participating in the study. To participate, 
stakeholders must have been employed by either of the 
sites as an administrator, health care provider, or social 
worker/case manager for at least 6  months, be at least 
18 years of age, and be able to understand and speak Eng-
lish and to provide written and verbal informed consent.
At-risk women will be recruited from the correctional 
facility for all phases of the study (Phase 1: n = 16–30; 
Phase 2: n = 8–12; Phase 3: n = 80). Announcements 
about the study will be made during group meetings by 
a trained research assistant, flyers about the study will be 
posted at the facility, and advertisements for the study 
will be included in facility newsletters. It will be made 
clear that participation is completely voluntary and that 
there are no consequences to legal status for participat-
ing or not participating. If an individual is interested in 
participating, the research assistant will set up a time 
to discuss the study with them further and screen them 
for eligibility. Study eligibility will be determined via a 
screening interview, medical record review, and consul-
tation with correctional facility staff. Eligibility criteria 
include: (1) female at birth; (2) at least 18 years of age; (3) 
not currently pregnant; (4) risk behavior prior to incar-
ceration that meets CDC indications for PrEP [38]; (5) it 
is clinically appropriate, within CDC guidelines, to initi-
ate PrEP [38]; (6) likely to be incarcerated for < 6 months; 
(7) able to understand and speak English and to provide 
written and verbal informed consent. For this population, 
Fig. 1 Brief description of the components and flow of the study phases
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CDC indications for PrEP include: HIV-positive sexual 
partner, recent bacterial STI (gonorrhea or syphilis), 
high number of sex partners, history of inconsistent or 
no condom use, commercial sex work, residence in high 
HIV prevalence area or network, HIV-positive injecting 
partner, or sharing injection equipment [38].
Procedures
Phase 1: individual interviews
Individual interviews will be conducted with the target 
population and key stakeholders to inform the interven-
tion content and materials as well as the implementation 
approach. All participants will be asked to volunteer their 
time for this phase of the study. The individual inter-
views will be conducted in a private space and will last 
60–90 min. After each interview, the research team will 
debrief and discuss emerging themes. We will regularly 
review saturation of key topics and conduct additional 
individual interviews if more information is warranted.
During the target population interviews, we will collect 
quantitative data regarding demographic information 
and HIV-related sex and drug risk behavior during the 
6  months prior to incarceration, based on CDC guide-
lines for PrEP indications for women. This informa-
tion will be used to stratify the sample by type of risk 
behavior (n = 6–10 women with sex risk only, n = 6–10 
women with drug risk only, and n = 6–10 women with 
sex and drug risk) and to perform analyses that exam-
ine differences in qualitative data. Interviews with the 
target population will include the following topics: (1) 
effect of incarceration on behavior, relationships, and 
the risk environment; (2) knowledge, interest, and atti-
tudes regarding PrEP; (3) perceived need for PrEP based 
on certain HIV risk behaviors; (4) perceived barriers and 
concerns to initiating PrEP during incarceration and 
linking to PrEP care post-release; (5) perceived facilita-
tors to PrEP care and suggestions for overcoming barriers 
to PrEP care at the correctional facility and post-release; 
(6) strengths and limitations of the proposed MI-NAV 
content and structure and suggestions to improve accept-
ability, feasibility, and efficacy of MI-NAV (see Fig. 2 for 
example questions).
During the stakeholder interviews, quantitative 
data regarding demographic information, length of 
employment, and position will be collected. Individual 
interviews with key stakeholders will cover: (1) imple-
mentation barriers and facilitators at the correctional 
facility and post-release; (2) strengths and limitations of 
the proposed MI-NAV content and structure and sugges-
tions to improve acceptability, feasibility and efficacy of 
MI-NAV; (3) knowledge of PrEP and perceptions of its 
utility (see Fig. 2 for example questions).
Coding and  analysis All individual interview sessions 
will be audio-recorded and transcribed. The qualitative 
data from the target population and key stakeholders will 
be triangulated [39] and analyzed using thematic analysis 
[40]. This strategy will allow the research team to develop 
Fig. 2 Examples of questions from individual interviews in Phase 1
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themes from the research questions and the narratives 
provided by the participants [41]. Research questions 
include: (1) What are the perceived barriers and facilita-
tors to initiating PrEP during incarceration and linking 
to community-based PrEP care upon re-entry into the 
community among cisgender women? (2) How do cer-
tain risk behaviors, such as injection drug use, impact 
the perceived need for PrEP? (3) What are the perceived 
barriers and facilitators to PrEP adherence and retention 
in care during incarceration and in community-based 
care among women? (4) What should be the content and 
structure of an intervention during incarceration, at the 
time of release, and post-release to maximize PrEP care 
among at-risk women? The research team will develop 
a preliminary coding structure based on the interview 
scripts. After each debrief session following the comple-
tion of an interview, the coding structure will be updated 
as repeating themes emerge from the data. This will lead 
to the creation of a final coding structure, in which the-
matic categories will be refined, merged, or subdivided 
into subcodes. Then, two independent coders will use 
the final coding structure to double code the transcribed 
interviews and an inter-coder reliability estimate will be 
computed. Standard analysis techniques will be utilized, 
including open coding, axial coding, marginal remarks, 
and memo-writing [40]. The data acquired from these 
methods will be used to inform intervention materials 
and the implementation approach.
Phase 2: pilot test of intervention materials and draft 
of implementation manual
All intervention materials will be created after the con-
clusion of the individual interviews in Phase 1. The SEM 
and feedback we receive from WEI and stakeholders in 
Phase 1 will create a framework that informs the devel-
opment of intervention materials. Once developed, we 
will conduct a preliminary test of the intervention with 
a total of 8–12 WEI who are at risk for HIV and meet all 
other study inclusion criteria. During this phase, partici-
pants will complete a baseline interview while incarcer-
ated, receive the MI-NAV intervention, and participate in 
an individual interview post-release. Participants will not 
be compensated for the baseline interview while incar-
cerated but will receive a $50 gift card for completing the 
individual interview post-release. At the conclusion of 
this phase, a final version of clinician and patient manu-
als, as well as training materials, will have been developed 
for the MI-NAV intervention.
MI‑NAV intervention While the specific content, struc-
ture, and implementation approach for MI-NAV will be 
guided by the SEM and data from the individual inter-
views conducted during Phase 1 and Phase 2, a basic out-
line of the intervention has been developed. Our initial 
plan is to deliver MI-NAV in two segments. The first seg-
ment will be aimed at promoting uptake of PrEP during 
incarceration. The second segment will be aimed at link-
ing at-risk women to community-based PrEP care upon 
release from incarceration. In the intervention’s current 
form, our plans are for the first segment to consist of an 
in-person 50-minute session with a study intervention-
ist. Master’s-level clinicians will be hired as study inter-
ventionists and will be trained to deliver intervention 
materials by the study’s principal investigator. During this 
session, the interventionist will review how certain behav-
iors, such as injection drug use, increase HIV risk and will 
employ motivational interviewing techniques to explore 
the participant’s interest in starting PrEP while incarcer-
ated. If the participant expresses an interest in beginning 
PrEP care, the interventionist will set up an appointment 
for the participant to initiate PrEP care with a provider 
from the correctional facility. The second segment of the 
intervention will begin 2 weeks before the participant is 
released from incarceration. It will first consist of a second 
in-person, 50-minute session with the same study inter-
ventionist. During this session, the interventionist will 
employ motivational interviewing techniques to either 
explore the participant’s interest in continuing PrEP care 
in the community once they are released or again discuss 
initiating PrEP care if the participant has not done so at 
this point. Strategies for overcoming obstacles to con-
necting to care in the community will also be discussed. 
When appropriate, referrals to community-based SUD 
treatment will be provided. If the participant wishes to 
continue or start PrEP care once they are released, the 
interventionist will facilitate the initial PrEP appointment 
scheduling with the community-based PrEP care provider 
and accompany the participant to the initial appointment. 
Following release, the same interventionist will conduct 
either a monthly face-to-face or telephone check-ins with 
the participant, whichever is preferred by the participant, 
for 6  months. These check-ins will be brief, but will be 
allowed to last up to 50 min if needed. They will each con-
sist of: (1) a review of recent HIV risk behavior, includ-
ing substance use, and referrals to community-based SUD 
treatment when appropriate; (2) discussion of PrEP and 
problem solving for barriers to PrEP adherence; (3) dis-
cussion of other HIV risk reduction strategies.
Refinement of  MI‑NAV The purpose of the individual 
interviews post-release will be to elicit feedback about 
the MI-NAV intervention, including any strengths and/or 
limitations perceived by the pilot participants (see Fig. 3 
for example questions). The same coding and analysis 
methods described above will be utilized for the qualita-
tive data collected during this phase of the study. Specifi-
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cally, we will look for repeating themes from the narra-
tives provided by the first 4–6 pilot participants and make 
adjustments to the intervention accordingly. This entire 
process will then be repeated again with another 4–6 pilot 
participants, leading to a final version of the MI-NAV 
intervention.
Phase 3: pilot RCT 
For the pilot RCT, 80 participants will be recruited and 
assigned to a condition using a 3:1 ratio, with 60 partici-
pants assigned to MI-NAV and 20 participants assigned 
to SOC. Participants in the SOC condition will also meet 
with a study interventionist twice while incarcerated. 
During the first session, SOC participants will receive a 
pamphlet regarding PrEP during incarceration and will 
be informed that they can initiate PrEP by speaking with 
a provider from the correctional facility. Mirroring MI-
NAV, the second session will occur 2  weeks before the 
participant is released from incarceration. This session 
will involve a referral to community-based PrEP care if 
the participant is interested and referral to community-
based SUD treatment when appropriate. Participants 
will be randomly assigned to condition using urn rand-
omization; the urn blocking variable will be baseline level 
of HIV risk behavior as assessed by the HIV Risk Assess-
ment Battery (RAB) [42]. The 3:1 randomization ratio 
will allow us to maximize the information gained about 
the MI-NAV intervention while including a comparison 
condition. RCT participants will complete a baseline 
interview while incarcerated and follow-up interviews 
at 1, 3, and 6  months post-release from incarceration. 
Baseline and follow-up interviews will be conducted 
by research assistants who will be blind to participants’ 
assigned condition. RCT participants will receive gift 
cards in the amount of $25, $30, and $50, respectively, for 
the 1-, 3-, and 6-month follow-ups (see Table 1 for timing 
of Phase 3 protocol elements). No compensation will be 
provided for the baseline interview or sessions/check-ins 
with the interventionist.
Measures The primary outcome for this study is link-
age to community-based PrEP care post-release. Second-
ary outcomes include PrEP initiation during incarcera-
tion, PrEP adherence, and retention in PrEP care. HIV 
and other STI test results will be extracted from medical 
records, and an HIV test will be performed for research 
purposes at the 6-month follow-up. Acceptability and fea-
sibility of the intervention will also be assessed. Additional 
quantitative data will be collected during the baseline and 
follow-up assessments (see Table 2).
PrEP care initiation and linkage to care Information will 
be extracted from participants’ medical records at the cor-
Fig. 3 Example questions from individual interviews post‑release in 
Phase 2
Table 1 Timing of participant enrollment, receipt of intervention, and assessment activities during Phase 3
Timepoint Enrollment Baseline Post-allocation









Primary outcomes X X X
Secondary outcomes X X X
Other outcomes X X X X
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rectional facility regarding whether PrEP was prescribed 
and whether PrEP was administered each day during the 
period of incarceration. Linkage to community-based 
PrEP care is operationalized as receipt of a prescrip-
tion for PrEP from a community-based provider within 
3 months of release from incarceration, verified through 
medical record data extraction. This time window was 
selected because it is consistent with the CDC’s guidelines 
for PrEP follow-up visits (every 3 months) [38].
PrEP adherence and care retention PrEP adherence will 
be determined by drug concentrations of emtricitabine/
tenofovir in dried blood spot samples collected from par-
ticipants who have been prescribed PrEP at 3- and 6-month 
follow-ups. The lower limit of quantification for this test, 
or ability to detect drug concentrations, is 10 ng/ml [43]. 
Values under 10 ng/ml will be treated as “undetectable.” 
Drug concentrations will be entered as continuous vari-
ables for data analysis. Self-reported adherence will also 
be assessed using a well-validated 3-item measure, known 
simply as the Three-Item Self-Report Measure for Medi-
cation Adherence [44]. The three items focus on the past 
30 days and include: 1) an assessment of how many doses 
of medication were missed, 2) a self-rating of how well 
the participant managed to take their medication in the 
way they were instructed, and 3) a self-rating of how often 
the participant managed to take their medication in the 
way they were instructed. Retention in PrEP care is being 
defined as attendance to 3-month (± 1  month) clinical 
appointments in accordance with current CDC guidelines 
for PrEP care [38]. These guidelines include follow-up vis-
its at least every 3 months to determine if it is clinically 
appropriate to continue PrEP care. These visits typically 
involve testing for HIV, bacterial STIs, pregnancy, and 
assessment of renal function. Attendance to follow-up 
PrEP appointments will be extracted from participants’ 
medical records.
Potential moderators of  treatment effects It is pos-
sible that certain variables may be potential modera-
tors of treatment effects. Alcohol and drug use [24–26], 
HIV risk behaviors [45, 46], housing status [47, 48], and 
depressive symptoms [27] have been found to be associ-
ated with poor treatment engagement and medication 
adherence in previous research. Therefore, we will be col-
lecting information about these variables for exploratory 
analyses. The Timeline Follow Back (TLFB), a calendar-
assisted structured interview, will be used to collect data 
Table 2 Schedule of assessments
a Extracted from participants’ medical records
b Collected only at 3 and 6 months
c Collected only at 6 months
Quantitative measures Screen Baseline 1-, 3-, 
and 6-months 
follow-up
Inclusion/exclusion criteria (including negative HIV and pregnancy test) X
Descriptive information
Demographics X X
PrEP care initiation during incarceration and linkage to care in community Xa
PrEP care retention Xa,b
PrEP adherence
Dried blood spot test Xb
Self‑reported adherence X
HIV test results Xa Xc
Other STIs, hepatitis B, hepatitis C test results Xa
Potential moderators of treatment effects
Timeline followback for alcohol and drug use (TLFB) X X
Timeline followback for HIV sex and drug risk behavior and HIV risk assessment battery 
(RAB)
X X
Center for Epidemiologic Studies Depression Scale (CES‑D) X X
Treatment received: treatment services review X X
Use of medications/pregnancies X X
Intervention acceptability Xc
Intervention feasibility Xc
Reasons for linkage/non‑linkage to PrEP Care/risk reduction Xc
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on the number of standard drinks consumed per day and 
types of drug classes used each day within a given time 
period [49–51]. The TLFB will also be used to assess daily 
HIV drug and sex risk behaviors. In addition, the HIV 
Risk Assessment Battery (RAB) will serve as a measure 
of overall HIV sex and drug risk behavior [42]. The RAB 
assesses the frequency of behaviors such as injection drug 
use, sex without a condom, sex while under the influence 
of substances, and sex in exchange for money or drugs. 
Frequencies fall on scales with response options between 
a range of 0 (least frequent option, depending on behav-
ior) to 3 (most frequent option, depending on behavior). 
An overall risk score, which is correlated with serocon-
version, is computed by adding the values corresponding 
with the response option (e.g. 0–3) and then dividing this 
total score by the highest possible score. Information on 
housing status will be collected, along with other demo-
graphic information, at baseline and each of the follow-up 
appointments. Finally, the Center for Epidemiologic Stud-
ies Depression Scale (CES-D) will be used to measure 
level of depressive symptoms [52].
Intervention feasibility and acceptability At the conclu-
sion of the study, we will compile a patient eligibility rate, 
enrollment refusal rate, rate of recruitment, and follow-
up completion rate in order to evaluate the feasibility of 
conducting a subsequent larger scale study using this 
protocol. We will also compile a study dropout rate and 
intervention session completion rate, as indices of accept-
ability. In addition, the 8-item Client Satisfaction Ques-
tionnaire-Revised will be used to further evaluate inter-
vention acceptability and feasibility [53].
Reasons for PrEP care linkage and non‑linkage/risk reduc‑
tion strategies During the 6-month follow-up assess-
ment, all participants will complete a brief qualitative 
interview in which they will be asked to reflect on factors 
that impacted their use or non-use of PrEP both while 
incarcerated and after release. Participants will also be 
asked about any other HIV risk reduction strategies that 
were employed. During analysis, participants’ responses 
will be stratified and examined based on level of PrEP 
uptake per condition.
Planned data analysis
REDCap, a secure web application, will be used as the 
primary data tracking, data collection, and data man-
agement platform for all assessments. Quantitative data 
analyses will be conducted only on participants recruited 
during Phase 3 (i.e., once random assignment has begun). 
As a first step, the equivalence of treatment conditions 
with regard to key baseline variables will be assessed. 
This will involve comparisons of treatment conditions on 
demographic characteristics and baseline levels of poten-
tial treatment moderators. Should conditions differ on 
any characteristic, these variables will be placed in mod-
els as interactions with group assignment along with its 
main effect and also in a distinct model with the inter-
action removed. The model with the lowest AIC will be 
retained. Other preliminary analyses will include studies 
of patterns of missing data, research dropout rates, dis-
tributional properties of dependent and other measures, 
and correlations among outcomes measures.
Data analysis will follow a sequence designed to exam-
ine the primary outcome questions: (1) Does MI-NAV 
lead to higher rates of linkage to community-based PrEP 
care? (2) Does MI-NAV lead to better PrEP adherence, 
based on dried blood spot tests (DBS), compared to 
SOC? (3) Does MI-NAV lead to better retention in care 
compared to SOC? There is little expectation of observed 
HIV seroconversion, given the modest sample size and 
6-month follow-up window. However, seroconversion 
rates of each condition will be examined. Analyses will 
also be conducted to examine the relative impact of MI-
NAV versus SOC on self-reported PrEP adherence. Fol-
lowing the intention-to-treat principle, all randomized 
participants will be included in the analyses. We antici-
pate an attrition rate less than 10%, which will provide 
us with a final sample size of at least 54 participants in 
the MI-NAV condition and 18 participants in the SOC 
condition. This estimate is based on previous research 
with a high-risk, incarcerated population, in a geographi-
cally similar setting, which retained 96% of participants 
at 12-month follow-up [54]. In addition, we will employ 
retention strategies that increase retention rates in this 
population [55], including: (1) offering interview incen-
tives that are higher than normal hourly rates of pay and 
providing transportation to and from interview locations; 
(2) conducting regular phone check-ins or sending let-
ters between appointments to ensure contact informa-
tion has not changed; (3) collecting contact information 
of secondary contacts, such as friends or relatives, that 
will know how to reach the participant; and 4) working 
with local criminal justice agencies, parole officers, and 
police departments that can help maintain or reestablish 
contact with participants if necessary.
Given that this is a pilot study, the primary goal is to 
yield a stable estimate of the effect size rather than to 
find statistically significant differences. The effect size 
estimate will be useful in planning a future RCT. We are 
aware of the dangers of relying exclusively on small pilot 
studies to gauge the promise of interventions [56]. These 
effect size estimates have a large standard error, and we 
primarily will be hoping to find a pattern of results that is 
supportive of MI-NAV, at which point a full scale trial will 
be designed to test for a clinically meaningful effect size. 
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To provide stable odds ratios for estimates of effect size 
for dichotomous or categorical variables, such as PrEP 
care linkage, a somewhat larger sample size is required. 
For continuous variables, group means typically begin to 
stabilize around 15 participants per group. We believe 
that the sample size of 60 participants in MI-NAV and 20 
participants in SOC, even after attrition, will allow us to 
evaluate the potential of MI-NAV to improve PrEP link-
age while maximizing the number of participants in the 
MI-NAV condition in order to fully assess the feasibility 
and acceptability of the intervention.
Primary RCT analyses
Tests of the effects of treatment on the primary outcome 
variable (linkage to community-based PrEP care) and 
secondary outcomes (PrEP DBS adherence and reten-
tion in care at 3 and 6 months) will be conducted using 
a fractional logit model [57] estimated by Generalized 
Estimating Equations (GEE) [58–60]. GEE is a quasi-like-
lihood estimation method of repeated measures analysis 
for appropriate modeling of covariance structures when 
outcomes are correlated across time. Additionally, it 
allows for the inclusion of both categorical and continu-
ous independent variables. While it is most common to 
use logistic regression to analyze dichotomous variables, 
the fractional logit model can be used for any fractional 
outcome with a range of 0–1. An advantage of GEE over 
ANOVA is that GEE models nesting by adjusting the 
standard errors of the test statistics based on the covari-
ances (and variances) of nested observations, rather than 
depending on calculating differences. These variances 
and covariances can be modeled based on all data avail-
able. Therefore, a subject with missing data for one time 
point will not contribute to the variance or covariance 
estimates involving that time point, but their non-miss-
ing time points will be used to estimate those variances 
and covariances.
The primary, between groups, independent variable in 
the above GEE is treatment group. Variables measured at 
baseline will be examined using screening runs prior to 
primary analyses to see which of these baseline measures 
are most strongly associated with the outcomes (linkage 
to PrEP, PrEP DBS adherence, retention in PrEP care, 
and self-reported adherence). Those that show significant 
relationships with outcome will be entered as covariates 
in the primary analyses unless there are concerns over 
multicollinearity. The linear effect of time will also be 
included as a covariate in these analyses, as we assume 
that retention and adherence rates will show a tendency 
to decrease over time. We will also test for non-linear 
(i.e., linear plus quadratic) effects of time for the repeated 
measures, adherence and retention. Testing the time 
by group interaction will indicate the extent to which 
treatment differences are more or less pronounced over 
time.
Analyses will be conducted separately on two overlap-
ping samples. Following the intention-to-treat principle, 
all randomized participants will be included in the first 
set of analyses. This is the most conservative approach 
and represents our main outcome analysis. Analyses 
will also be conducted on subjects who completed the 
assigned intervention, the “as-treated” analysis. Although 
subject to more bias, especially if attrition rates are high, 
this latter approach answers more directly the ques-
tion of intervention efficacy by providing an estimate of 
the maximal effects attained by an intervention. Similar 
results with both approaches increases confidence in the 
findings.
Missing data
In our experience, missing data is unavoidable. However, 
every effort will be made to minimize and appropriately 
handle missing data. Follow-up data will be gathered 
regardless of whether the intervention was received, and 
follow-up will be vigorously pursued to minimize miss-
ing data. Participants will be followed independent of 
whether they are engaged in PrEP care. If a participant 
is re-incarcerated during the follow-up period, we plan 
to work with the correctional facility to continue to fol-
low them and avoid loss to follow-up. In addition, we will 
request permission to collect data from medical records 
for participants who do not complete a follow-up.
Whenever possible, we will collect and summarize the 
reasons participants drop out of the study. We will also 
evaluate missing data to determine if there are mecha-
nisms that help to explain why data are missing and will 
utilize multiple imputation techniques [61]. Variables 
collected at baseline, such as demographic information, 
alcohol and drug use prior to incarceration, and HIV 
risk behaviors prior to incarceration, will be compared 
between participants retained throughout the study and 
participants who missed follow-up appointments. To 
increase confidence in our findings, sensitivity analyses 
will be performed with and without the missing data, 
using imputed data from the individuals with whom we 
lose contact.
Discussion
Women with criminal-justice involvement are among the 
most vulnerable and heavily impacted by HIV [1], con-
sistently reporting high rates of both sex and drug risk 
behavior [2, 3, 62, 63]. The link between risk behavior 
and incarceration is unsurprising given that many of the 
behaviors that place women at risk for HIV, such as injec-
tion drug use and transactional sex, also put them at risk 
for incarceration. Further, the time immediately following 
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release from incarceration appears to be a particularly 
high risk period for HIV-related risk behavior among 
women [4–6]. PrEP can be a highly effective means of 
preventing HIV infection among at-risk women [9–11]. 
Currently, PrEP is underutilized among US women who 
are at risk for HIV [12, 14]. This protocol seeks to address 
the great need to engage women at risk for HIV in PrEP 
care, capitalizing on a period of incarceration as an 
opportunity to reach a high-need, vulnerable population.
While this study will advance our knowledge of bar-
riers and facilitators to PrEP care among women at risk 
for HIV upon release from incarceration, there are some 
limitations that warrant recognition. First, since the goals 
of the study are to establish effect size estimates and to 
determine the feasibility and acceptability of the inter-
vention, a modest sample size will be recruited. There-
fore, it is unlikely that we will find statistically significant 
differences between treatment conditions. Second, due 
to the pilot nature of the current study, recruitment will 
occur at a single correctional facility. This impacts our 
ability to generalize the findings to other correctional 
settings and locations. If the intervention appears to be 
effective at promoting uptake of PrEP during incarcera-
tion and linkage to PrEP care post-incarceration, future 
research should employ a significantly larger sample size 
and multi-site recruitment to address these limitations.
Despite the aforementioned limitations, this study has 
the potential to significantly inform the field. Since risk 
of acquiring HIV is disproportionate within this popula-
tion relative to others due to both elevated rates of sex 
and drug risk behavior, it is essential to develop tailored 
interventions that reduce their HIV risk as they reenter 
the community. Therefore, engaging at-risk women in 
PrEP care before and after release from incarceration has 
the potential to reduce their risk of acquiring HIV. How-
ever, women recently released from incarceration experi-
ence many barriers to receiving care, including substance 
use, stigma, and lack of transportation [28, 29, 64]. To be 
effective, an intervention will need to consider these bar-
riers in order to facilitate linkage with community-based 
treatment. If successful, the MI-NAV intervention will 
increase uptake and linkage to PrEP care and thereby 
substantially reduce HIV seroconversion among this 
population. More broadly, if this treatment approach is 
effective, it could be applied to other types of treatment 
post-incarceration, such as treatment for SUD.
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